Skip to main content
|

Add a bookmark to get started

Bookmarks info
Patrick J. O'Malley

Patrick J. O'Malley

Partner
San Diego
About

Patrick O'Malley is a partner in the San Diego office focusing his practice on representing issuers and investment banks in capital markets transactions.  Patrick regularly advises clients listed on the NASDAQ Stock Market, NYSE and NYSE American, as well as international exchanges. Patrick principally represents established and emerging life sciences, biotech, medical device, and technology companies, providing guidance on a range of matters, including corporate governance, SEC periodic and current reporting, proxy statements, and related corporate and disclosure advice.

Patrick also represents both selling companies and acquirers in merger and acquisition transactions, primarily representing public clients and private clients merging into public shell companies. Patrick has advised numerous private companies in venture capital financing and corporate governance and Board of Director matters. 

Areas of FocusCorporateEmerging Growth and Venture CapitalEquity Capital Markets
Bar admissionsCalifornia

EXPERIENCE

Representative Matters
  • Zeltiq Aesthetics (Nasdaq: ZLTQ) in its US$105 million initial public offering
  • Neothetics in its US$65 million initial public offering and its sale to Evofem Biosciences
  • Nexvet Biopharma (Nasdaq: NVET) in its US$40 million initial public offering
  • Sientra in its US$115 million follow‑on offering
  • Halozyme Therapeutics, Inc. in numerous follow‑on offerings
  • GenMark Diagnostics (Nasdaq: GNMK) in its initial public offering and numerous follow‑on offerings
  • Maxwell Technologies in its follow‑on offering and convertible note offering
  • DragonWave (Nasdaq: DRWI; TSX: DRI) in numerous follow‑on offerings
  • Cytori Therapeutics (Nasdaq: CYTX) in numerous follow‑on offerings and rights offering
  • Mast Therapeutics, Inc. in its sale to Savara and in numerous follow‑on offerings
  • QUALCOMM Incorporated in numerous acquisitions, venture financings and other strategic transactions
  • DTS in its US$1.0 billion sale to Tessera Technologies, as well as numerous acquisitions
  • NuVasive in its US$650 million 2.25% Convertible Senior Note offering and numerous acquisitions
  • P.F. Chang's China Bistro in its US$1.1 billion sale to Centerbridge Partners
  • The Active Network, Inc. in its US$1.05 billion sale to Vista Equity Partners
  • Life Technologies Corporation in various acquisitions, venture financings and other strategic transactions
  • Reva Medical (ASX: RVA) in its convertible note offerings
  • aTyr Pharma Inc. in its venture financings and other strategic transactions
  • Epic Sciences, Inc. in its venture financings and other strategic transactions
Education
  • J.D., Georgetown University Law Center 2010
    Member, The Tax Lawyer
  • B.A., University of Notre Dame 2007

Awards

The Legal 500 United States

  • Recommended, Capital Markets: Equity Offerings (2024)
  • Recommended, Capital Markets Equity Offerings – Advice to Issuers (2024)
  • Recommended, Capital Markets Equity Offerings – Advice to Managers (2023-2024)

Prior Experience

  • Judicial Extern to Honorable Marilyn Huff, Southern District of California

My latest insights

News

DLA Piper advises Palomar Holdings, Inc. in pricing of public offering of common stock

26 August 2024 .1 minute read

News

DLA Piper advises Iovance in the offering of US$211 million of shares of common stock

26 February 2024 .2 minute read

News

DLA Piper advises Iovance in the offering of US$172.5 million of shares of common stock

17 July 2023 .2 minute read

View All

Connect

Phone

+1 858 677 1471
(Work, San Diego)
CallvCardLinkedInPrint
Privacy policyLegal noticesCookie policyModern slaveryWhistleblowingFraud AlertSitemap

DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.

© 2024 DLA Piper